3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
7
Polycystic Ovary Syndrome
5
Ovarian Hyperstimulation Syndrome
3
Infertility
3
Breast Neoplasms
2
The Neoadjuvant Therapy
1
Sarcoma, Ewing
1
Sarcoma
1
Osteosarcoma
1
Neoplasms
1
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
1
Lymphoma
1
Helping Behavior
1
Interventions
Methotrexate
5
Drug Therapy
5
apatinib
4
Neoadjuvant Therapy
4
Doxorubicin
3
camrelizumab
2
Ifosfamide
2
Cisplatin
2
trilaciclib
1
spartalizumab
1
palbociclib
1
isophosphamide mustard
1
irinotecan sucrosofate
1
glucarpidase
1
endostar protein
1
Zoledronic Acid
1
Vinorelbine
1
Triptorelin Pamoate
1
Trabectedin
1
Therapeutics
1
Thalidomide
1
TQ-B3525
1
Psychiatric Rehabilitation
1
Nivolumab
1
Neuropsychological Tests
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Microbiota
1
Metabolome
1
Magnetic Resonance Spectroscopy
1
Lithium Carbonate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Osteosarcoma
×
Triptorelin Pamoate
×
Clear all
NCT02856048
2019-12-17
PRESOV
Assistance Publique - Hôpitaux de Paris
Phase 2/3
Unknown
11 enrolled